The impact of tumor heterogeneity on implementing the various branches of precision oncology (e.g., strategies targeting p53, p21, DNA-damage response, regulated cell death, etc.)is becoming increasingly appreciated (e.g., [72,73,74,75,76,77,78,79,80,81,82]). The gene discussed is TP53; the disease is neoplasm.